Why the study?
Do antiplatelet agents or oral anticoagulants prevent aorto-coronary bypass occlusion in patients undergoing venous bypass grafts?
Do antiplatelet agents or oral anticoagulants prevent aorto-coronary bypass occlusion in patients undergoing venous bypass grafts?
Answers are grounded in this paper and cite their sources.
Dipyridamole combined with aspirin appears to be the most effective regimen for preventing aorto-coronary venous bypass graft occlusion, while oral anticoagulants show no significant benefit.
The cumulative occlusion rates of aorto-coronary artery venous bypass grafts average from 16 to 26% per distal anastomosis within 12 months and about 2% per following year. The potential benefit of oral anticoagulants and platelet inhibitor drugs has been tested to prevent graft occlusion and to retard the atherosclerotic process. Oral anticoagulants started on the third postoperative day do not significantly reduce graft occlusion after 6 months. Among the platelet inhibitor drugs, dipyridamole started before surgery, followed by dipyridamole and aspirin soon after surgery, was the drug regimen with the best results. More randomised double-blind clinical trials are highly desirable to confirm these findings and to resolve the question of relative efficacy and safety for the various drugs reported to have shown benefit when used in combination.
No takes yet. Share an insight, caveat, or question.
Verstraete et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: